Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine January 2018, 59 (1) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

ORBITA endpoints: Dilsizian and Erario offer a critical review of primary and secondary endpoints in the Percutaneous Coronary Intervention in Stable Angina clinical trial.

Page 1

Maximizing total-body PET: Cherry and colleagues discuss their efforts to develop and apply a first-generation total-body PET/CT scanner, the benefits of increasing body coverage, and likely clinical results of improvements in time-of-flight PET.

Page 3

Challenging nuclear cardiology research: Dilsizian comments on ways to increase the relevance of research in all areas of nuclear cardiology, with a special focus on factors currently limiting progression to routine clinical use.

Page 13

Immune patterns of response in HL: Dercle and colleagues investigate 3-month 18F-FDG PET/CT for identification of patients with Hodgkin lymphoma responding to immune-checkpoint blockade by anti–programmed death 1 antibodies and describe new immune response and progression patterns.

Page 15

18F-FDG PET/CT in pediatric osteosarcoma: Davis and colleagues explore the relationship of 18F-FDG uptake in primary tumor at diagnosis, during therapy, and after therapy with histologic response and event-free survival in pediatric and young adult patients with osteosarcoma.

Page 25

18F-FDG PET and gene networks: Na and Choi identify and investigate gene networks associated with tumor metabolism and their biologic function, using RNA sequencing and 18F-FDG PET data.

Page 31

64Cu-trastuzumab uptake in breast cancer: Mortimer and colleagues characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab on PET/CT and standard immunohistochemistry-based classification of human epidermal growth factor receptor 2 status in women with metastatic breast cancer.

Page 38

FMT/CT and PET/MR imaging: Hage and colleagues compare in squamous cell carcinoma xenografts the performances of advanced fluorescence-mediated tomography/CT and PET/MR imaging in quantitative assessment of biodistributions of different antibody formats and their dependence on specific labels.

Page 44

89Zr-transferrin vs. 18F-FDG PET in TNBC: Henry and colleagues compare 89Zr-transferrin and 18F-FDG PET imaging in vitro and in preclinical models of triple-negative breast cancer, with a focus on the ability of 89Zr-transferrin to identify expression of the MYC oncogene.

Page 51

Cerenkov-activated tagging: Das and colleagues describe research on a strategy to enable targeted Cerenkov luminescence–activated drug delivery to cancer cells and report on a tagging method for associated fluorescence imaging.

Page 58

AUC for SSTR PET: Representatives from 9 nuclear medicine, imaging, and oncology organizations provide consensus appropriate use criteria intended for referring medical practitioners on the use of somatostatin receptor PET in patients with neuroendocrine tumors.

Page 66

Single-sample dosimetry after 177Lu-DOTA: Hänscheid and colleagues describe a method for dosimetry simplification in 177Lu-DOTATATE/DOTATOC therapy, allowing calculation of absorbed doses from a single SPECT/CT assessment of abdominal activity distribution 4 days after treatment.

Page 75

68Ga-PSMA PET/CT and PC management: Roach and colleagues report on the results of an Australian multicenter study assessing whether 68Ga-prostate-specific membrane antigen PET/CT imaging affects management intent in patients with primary and/or recurrent prostate cancer.

Page 82

Management after 68Ga-PSMA PET/CT: Afaq and a team of international researchers detail the impact of 68Ga-prostate-specific membrane antigen PET/CT on management of prostate cancer in patients with biochemical recurrence.

Page 89

Radionuclide targeting with ADAPT: Lindbo and colleagues determine whether the use of a nonresidualizing label or different label placement improves the targeting properties of albumin-binding domain–derived affinity scaffold protein-6, a tracer for human epidermal growth factor receptor 2 expression.

Page 93

Hypercapnia and MBF: Pelletier-Galarneau and colleagues document the pharmacodynamics of CO2 for myocardial blood flow using prospective end-tidal targeting to precisely control arterial Pco2 and PET to assess myocardial blood flow.

Page 100

Pseudoreference regions for 11C-PBR28 PET: Albrecht and colleagues evaluate various ratio approaches for translocator protein PET imaging and compare these with standard kinetic modeling techniques in patients with chronic low back pain or amyotrophic lateral sclerosis and healthy controls.

Page 107

Off-target labeling of AV-1451: Barrio provides perspective on the rapid adoption of this agent for tau imaging with PET, reviews reports that it is less than ideal for clinical applications, and previews a related article in this issue of JNM.

Page 115

18F-AV-1451 and iron: Choi and colleagues investigate the relationship between 18F-AV-1451 off-target binding in the basal ganglia of elderly patients on PET and iron accumulation using iron-sensitive R2* MR imaging.

Page 117

Thyroid stunning by contrast agents: Vassaux and colleagues ask whether it is the free iodide in iodinated imaging contrast media or the media themselves that reduce thyroid uptake on diagnostic thyroid scintigraphy and complicate radioiodine treatment of thyroid malignancies.

Page 121

PET/CT in chronic Q fever: Kouijzer and colleagues from multiple Dutch research sites explore the diagnostic, management, and prognostic value of 18F-FDG PET/CT in chronic Q fever at diagnosis and during follow-up.

Page 127

Imaging bacterial infection with 18F-FDS: Li and colleagues validate 2-18F-fluorodeoxysorbitol as a potential radiopharmaceutical for longitudinal imaging bacterial infection and differentiating K. pneumoniae lung infection from inflammation.

Page 134

First KOR PET 18F tracer: Li and colleagues synthesize and evaluate 18F-LY2459989, a κ-opioid receptor–antagonist radiotracer, in nonhuman primates and compare it with 11C-LY2459989.

Page 140

18F-MFBG imaging of neuroendocrine cancer: Pandit-Taskar and colleagues report on a first-in-human study of 18F-meta-fluorobenzylguanidine PET imaging to evaluate its safety, feasibility, pharmacokinetics, and dosimetry in patients with neuroendocrine tumors.

Page 147

OLINDA/EXM 2.0 compendium: Stabin and Siegel present a compendium of about 100 radiopharmaceuticals, based on the OLINDA/EXM version 2.0 software and using a new generation of voxel-based, realistic human computational phantoms to develop dose estimates.

Page 154

89Zr-trastuzumab in esophagogastric cancer: O’Donoghue and colleagues evaluate the safety, pharmacokinetics, biodistribution, and dosimetry of 89Zr-trastuzumab in human epidermal growth factor receptor 2–positive esophagogastric adenocarcinoma.

Page 161

PET stability during aggressive MR: Deller and colleagues test the PET stability of a whole-body PET/MR system during simultaneous scanning of intensive MR pulse sequences, with resulting promise for demanding applications such as kinetic modeling.

Page 167

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (1)
Journal of Nuclear Medicine
Vol. 59, Issue 1
January 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jan 2018, 59 (1) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jan 2018, 59 (1) 6A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
  • The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
  • 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor
  • Validation of 2-18F-Fluorodeoxysorbitol as a Potential Radiopharmaceutical for Imaging Bacterial Infection in the Lung
  • Comparison of the Accuracy of FMT/CT and PET/MRI for the Assessment of Antibody Biodistribution in Squamous Cell Carcinoma Xenografts
  • The Irony of PET Tau Probe Specificity
  • Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation
  • Cerenkov-Activated Sticky Tag for In Vivo Fluorescence Imaging
  • Effects of Hypercapnia on Myocardial Blood Flow in Healthy Human Subjects
  • Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
  • Challenging Nuclear Cardiology Research: Stimulating Discovery, Validation, and Clinical Relevance
  • PET Imaging Stability Measurements During Simultaneous Pulsing of Aggressive MR Sequences on the SIGNA PET/MR System
  • Pseudoreference Regions for Glial Imaging with 11C-PBR28: Investigation in 2 Clinical Cohorts
  • Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates
  • Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer
  • Tumor Metabolic Features Identified by 18F-FDG PET Correlate with Gene Networks of Immune Cell Microenvironment in Head and Neck Cancer
  • Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
  • Iodinated Contrast Agents Perturb Iodide Uptake by the Thyroid Independently of Free Iodide
  • 18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma
  • Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
  • Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management
  • Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
  • Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
  • RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0
  • The Value of 18F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever
  • Is Exercise Treadmill Time or Reduction in Myocardial Ischemia the Appropriate Primary Endpoint to Assess Success of Percutaneous Coronary Intervention in Stable Angina (ORBITA)?
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire